Japanese scientists have successfully used genetically engineered cells from the tobacco plant to produce a human antibody that homes in on a molecule on the surface of the hepatitis B virus (HBV). Currently, treatment of HBV may include infusion of serum containing antibodies, called immunoglobulin, collected from blood donors.
